Your local Gilbride Pharmacy is here to support you by giving you tips about effective weight loss and management while guiding you to a healthy eating lifestyle and maintaining your weight.
We offer the following options:
- Weight loss injection (Wegovy)
- Weight loss injection (Saxenda)
- Weight loss injection (Mounjaro)
- Weight loss capsules (Orlistat)
- Weight loss tablets (Mysimba)
Visit Us
Take control of your health journey with Gilbride Pharmacy. Select your preferred branch to visit their page and inquire about this service or simply walk in when it suits your schedule.
Details
Gilbride Pharmacy provides a comprehensive solution for achieving sustained and healthy weight loss. Benefit from ongoing advice and support, coupled with prescription medication treatment. Wegovy/Saxenda/Mounjaro act on areas of the brain which are involved in regulating your appetite. It increases feelings of fullness, reduces feelings of hunger and reduces the preference for high-fat foods. It reduces blood sugar by promoting the release of insulin when blood sugar levels are high. When combined with a calorie-controlled diet and increased exercise, it has proven to be effective in supporting weight loss.
An unhealthy lifestyle can contribute to various health conditions like type 2 diabetes and coronary heart disease.
You are eligible for our Weight Management Service if you are:
- Aged between 18 to 75
- Have a BMI of over 30
- Have a BMI of over 27, along with a diagnosis of a condition exacerbated by weight gain, such as a heart condition
More on Wegovy
Wegovy is 18-74- treatment with any weight loss
Treatment with Wegovy® should only be considered if dietary and physical activity interventions have been evaluated. It is vital that Wegovy® is used as part of an integrated approach to weight management, with the appropriate support, counselling and behavioural strategies available to the patient.
Contraception
Advise the patient that Wegovy® should not be used during pregnancy, and it is recommended to use contraception while using this medicine. If the patient wishes to become pregnant, they must stop using Wegovy® for at least two months in advance. Advise the patient if they become pregnant when using Wegovy®, they should contact their GP and treatment provider(1).
Diet
- Patients should be advised to adhere to the dietary recommendations they are given. This includes a nutritionally balanced, mildly hypocaloric diet, in addition to a diet that is rich in fruit and vegetables. Low calorie diets should not be undertaken without specialist supervision. Physical activity
- Patients should receive advice about increasing physical activity Acute pancreatitis
- Patients should be informed of the characteristic symptoms of acute pancreatitis and advised to discontinue treatment and seek medical advice if they occur. Further information can be found on the NHS website. Dehydration
- Patients should be advised of the potential risk of dehydration in relation to gastrointestinal side effects and take precautions to avoid fluid depletion (1). Symptoms of dehydration include dizziness, headache, fatigue, infrequent urination of small amounts, and dry mouth, lips and eyes
More on Mounjaro
Mounjaro is for ages 18-84
Acute pancreatitis
- Patients should be informed of the characteristic symptoms of acute pancreatitis and advised to discontinue treatment and seek medical advice if they occur. Further information can be found on Acute pancreatitis - Complications - NHS (www.nhs.uk). Dehydration
- Patients should be advised of the potential risk of dehydration in relation to gastrointestinal side effects and take precautions to avoid fluid depletion (1). Symptoms of dehydration include dizziness, headache, fatigue, infrequent urination of small amounts, and dry mouth, lips and eyes Diet
- Patients should be advised to adhere to the dietary recommendations they are given. This includes a nutritionally balanced, mildly hypocaloric diet, in addition to a diet that is rich in fruit and vegetables. Low calorie diets should not be undertaken without specialist supervision (2) .
Physical activity
- Patients should receive advice about increasing physical activity. Any advice given about exercise activities and duration should consider the person's current physical fitness and ability (2) Pregnancy (1)
- Tirzepatide should not be used during pregnancy or in women of childbearing potential not using contraception. If a patient wishes to become pregnant, tirzepatide should be discontinued at least 1 month before a planned pregnancy due to the long half-life of tirzepatide. Contraception (3)
- Patients using oral contraceptives, should consider also using a barrier method of contraception (e.g., a condom) or switching to a non-oral contraceptive method for 4 weeks after starting Mounjaro and for 4 weeks after each increase in dose Pregnancy (1)
- Tirzepatide should not be used during pregnancy or in women of childbearing potential not using contraception. If a patient wishes to become pregnant, tirzepatide should be discontinued at least 1 month before a planned pregnancy due to the long half-life of tirzepatide. Contraception (3)
- Patients using oral contraceptives, should consider also using a barrier method of contraception (e.g., a condom) or switching to a non-oral contraceptive method for 4 weeks after starting Mounjaro and for 4 weeks after each increase in dose